What is the global market size of Lung Cancer Therapeutics Market?

Global Lung Cancer Therapeutics Market size was valued at USD 24667.82 million in 2021 and is poised to grow from USD 27235.74 million in 2022 to USD 66407.15 million by 2030, growing at a CAGR of 10.41% in the forecast period (2023-2030).

Who are the key vendors in the Global Lung Cancer Therapeutics Market?

The top market participants have a wide geographic reach and a wide range of products to meet a variety of consumer wants. Industry players are spending a lot of money on R&D in order to introduce new Treatment and increase their profitability in this potential market 'AstraZeneca plc', 'F. Hoffmann-La Roche AG', 'Bristol-Myers Squibb Company', 'Merck & Co., Inc.', 'Pfizer Inc.', 'Novartis International AG', 'Eli Lilly and Company', 'Boehringer Ingelheim International GmbH', 'Takeda Pharmaceutical Company Limited', 'AbbVie Inc.', 'Sanofi S.A.', 'Astellas Pharma Inc.', 'Celgene Corporation', 'Eisai Co., Ltd.', 'Johnson & Johnson', 'Bayer AG', 'AbbVie Inc.', 'GlaxoSmithKline plc', 'Amgen Inc.', 'Spectrum Pharmaceuticals, Inc.'

What is the key driver of Global Lung Cancer Therapeutics Market?

The rise in chronic tobacco use is to blame for the rise in lung cancer cases, which now account for roughly 85% of all cancer cases worldwide. It is predicted that the number of cancer cases will increase in the near future due to cigarette smoke, which contains at least 73 known carcinogens.

What is the key market trend for Global Lung Cancer Therapeutics Market?

One of the key reasons fueling the expansion of the global lung cancer therapeutic market in 2021 is the rising adoption and demand for targeted medicines, which are regarded as the cornerstone of precision medicine due to the rising R&D activities. According to estimates, among the several therapeutic kinds, targeted therapy has the biggest market share. Targeted therapy held a market share of 51.1% and is expected to grow over the course of the forecast period. The expansion of the targeted therapy market is also being driven by a growing emphasis on lung cancer detection and subsequent treatment based on precise targeting of the tumour or cancer source.

Which region accounted for the largest share in Global Lung Cancer Therapeutics Market?

The lung cancer treatments and diagnostics market was dominated by North America in 2021, accounting for 39.17% of global value. The large percentage of elderly people in the region, the presence of numerous international and local manufacturers, and investments made to diagnose cancer at an earlier stage are only a few of the reasons for the market's expansion. However, throughout the predicted period of 2022–2028, Asia–Pacific is expected to have faster development. The region is making significant investments in radiology treatments and chemotherapies. China and Japan are prepared to raise their spending on cutting-edge immunotherapies.

Lung Cancer Therapeutics Market Companies

Lung Cancer Therapeutics Market Competitive Landscape

The top market participants have a wide geographic reach and a wide range of products to meet a variety of consumer wants. Industry players are spending a lot of money on R&D in order to introduce new Treatment and increase their profitability in this potential market

Lung Cancer Therapeutics Market Top Player’s Company Profiles

AstraZeneca plc
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Merck & Co., Inc.
Pfizer Inc.
Novartis International AG
Eli Lilly and Company
Boehringer Ingelheim International GmbH
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Sanofi S.A.
Astellas Pharma Inc.
Celgene Corporation
Eisai Co., Ltd.
Johnson & Johnson
Bayer AG
AbbVie Inc.
GlaxoSmithKline plc
Amgen Inc.
Spectrum Pharmaceuticals, Inc.

Lung Cancer Therapeutics Market Recent Development

In March 2022, AstraZeneca, PATH, and Qure.ai have teamed up to improve lung health in low- and middle-income countries. These three companies will collaborate to create a framework for using cutting-edge artificial intelligence technologies to detect lung cancer in patients undergoing chest screening for tuberculosis.
In March 2022, Duke University has joined Known Medicine, a rapidly expanding biotechnology company that specializes in finding potent anticancer medications, to determine the efficacy of the drugs for patients with lung cancer. Through this agreement, Known Medicine will be able to evaluate and improve their ODINTM platform. Both parties want to assess the platform's ability to predict clinical outcomes accurately in about 75 patients.

FAQs

Global Lung Cancer Therapeutics Market size was valued at USD 36.4 Billion in 2024 and is poised to grow from USD 41.2 Billion in 2025 to USD 111.1 Billion by 2033, growing at a CAGR of 13.2% during the forecast period (2026–2033).

The competitive landscape of the global lung cancer therapeutics market is characterized by a diverse range of pharmaceutical and biotechnology companies focused on developing innovative therapies. Omron, Merck, Bristol-Meyers Squibb, AstraZeneca and Pfizer are some of the major companies in the industry and are heavily focused on development of new treatments. Primary focus of development is product line expansion targeted at the increasing needs of effectively treating lung cancer with targeted therapies and immunotherapy. 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Pfizer Inc. (U.S.) ', 'Novartis AG (Switzerland) ', 'AstraZeneca PLC (UK) ', 'Merck & Co. Inc. (U.S.) ', 'Eli Lilly and Company (U.S.) ', 'Bristol Myers Squibb Company (U.S.) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Johnson & Johnson (U.S.) ', 'Amgen Inc. (U.S.) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'AbbVie Inc. (U.S.) ', 'GlaxoSmithKline plc (GSK) (UK) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Bayer AG (Germany) ', 'Dr. Reddy's Laboratories (India)'

The increasing lung cancer all over the globe is one of the major factors driving the global lung cancer therapeutics market trends. Tobacco consumption, environmental contamination, and evolution in lifestyle are some of the key factors resulting in the increase in the number of diagnosed cases, thus, resulting in increased demand for effective treatment methods and new therapies to improve patient care.

Rise of Personalized Medicine in Lung Cancer Treatment: There is a notable tendency in the global lung cancer therapeutics market, which is toward personalized medicine. Such an approach employs genetic profiling and biomarkers to design tailored treatments to suit individual patients. This trend increases the effectiveness of treatment and reduces the risk of adverse events and hence the need for targeted therapies and immunotherapies that correspond to specific patient’s cancer is increasing.

North America dominates the global lung cancer therapeutics market outlook due to several key factors, including advanced healthcare infrastructure, significant investment in research and development, and a high prevalence of lung cancer. Drug development and clinical trials are also on the increase owing to the presence of top pharmaceutical companies and biotechnology firms, which introduces a consistent flow of new therapies. In addition, robust cancer treatment regulation as well as health insurance for cancer treatment encourages the patients to access advanced treatment. The rising levels of awareness on lung cancer together with increased focus on early-stage diagnosis as well as personalized treatment plans also explains how the region adheres to the dynamic market quite effectively.

Lung Cancer Therapeutics Market

Report ID: SQMIG35J2088

Top Lung Cancer Therapeutics Companies

Lung Cancer Therapeutics Market Competitive Landscape

FAQs

Request Free Customization

Top Lung Cancer Therapeutics Companies

Lung Cancer Therapeutics Market Competitive Landscape

FAQs

What is the global market size of Lung Cancer Therapeutics Market?

Who are the key vendors in the Lung Cancer Therapeutics Market?

What is the key driver of Lung Cancer Therapeutics Market?

What is the key market trend for Lung Cancer Therapeutics Market?

Which region accounted for the largest share in Lung Cancer Therapeutics Market?

Request Free Customization